EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Tóm tắt
Từ khóa
Tài liệu tham khảo
Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. (eds) World Health Organization Histological Classification of Tumors of the Central Nervous System (International Agency for Research on Cancer, 2016)
Brat, D. J. et al. cIMPACT-NOW update 3: recommended diagnostic criteria for ‘Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV’. Acta Neuropathol. 136, 805–810 (2018).
Brat, D. J. et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 139, 603–608 (2020).
Louis, D. N. et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 30, 844–856 (2020).
Weller, M. et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18, e315–e329 (2017).
Brainin, M. et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. Eur. J. Neurol. 11, 577–581 (2004).
Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology 21 (Suppl. 5), v1–v100 (2019).
Rice, T. et al. Understanding inherited genetic risk of adult glioma - a review. Neurooncol. Pract. 3, 10–16 (2016).
Rasmussen, B. K. et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the danish neuro-oncology registry. J. Neurooncol. 135, 571–579 (2017).
Peeters, M. C. M. et al. Prediagnostic symptoms and signs of adult glioma: the patients’ view. J. Neurooncol. 146, 293–301 (2020).
Pace, A. et al. Determining medical decision-making capacity in brain tumor patients: why and how? Neurooncol. Pract. https://doi.org/10.1093/nop/npaa040 (2020).
Nayak, L. et al. The neurologic assessment in neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria. Neuro-Oncology 19, 625–635 (2017).
van den Bent, M. J. et al. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol. 19, 1170–1179 (2018).
Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
Nasreddine, Z. S. et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699 (2005).
Ellingson, B. M., Wen, P. Y. & Cloughesy, T. F. modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14, 307–320 (2017).
Albert, N. L. et al. Response assessment in neuro-oncology working group and european association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18, 1199–1208 (2016).
Le Rhun, E., Seoane, J., Salzet, M., Soffietti, R. & Weller, M. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer Lett. 480, 24–28 (2020).
Roth, P. et al. Neurological and vascular complications of primary and secondary brain tumors: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann. Oncol. https://doi.org/10.1093/annonc/mdx221 (2020).
Williams, M., Treasure, P., Greenberg, D., Brodbelt, A. & Collins, P. Surgeon volume and 30 day mortality for brain tumours in England. Br. J. Cancer 115, 1379–1382 (2016).
Eigenbrod, S. et al. Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir. 156, 1427–1440 (2014).
Hamisch, C. A. et al. Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield. Acta Neurochir. 161, 2065–2071 (2019).
Grasbon-Frodl, E. M. et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer 121, 2458–2464 (2007).
Millesi, M. et al. Is intraoperative pathology needed if 5-aminolevulinic-acid-induced tissue fluorescence is found in stereotactic brain tumor biopsy? Neurosurgery 86, 366–373 (2020).
Shirahata, M. et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 136, 153–166 (2018).
Banan, R. et al. Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol. 140, 569–581 (2020).
Reinhardt, A. et al. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathol. Commun. 7, 163 (2019).
Appay, R. et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology 21, 1519–1528 (2019).
Tesileanu, C. M. S. et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology 22, 515–523 (2020).
Reuss, D. E. et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 130, 407–417 (2015).
Wick, W. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81, 1515–1522 (2013).
Bady, P., Delorenzi, M. & Hegi, M. E. Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. J. Mol. Diagn. 18, 350–361 (2016).
Preusser, M. et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 18, 520–532 (2008).
Sahm, F. et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 131, 903–910 (2016).
Zacher, A. et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 27, 146–159 (2017).
Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018).
Ferguson, S. D. et al. Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas. J. Neuropathol. Exp. Neurol. 77, 437–442 (2018).
Stichel, D. et al. Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathol. 138, 827–835 (2019).
Stummer, W. et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7, 392–401 (2006).
De Witt Hamer, P. C., Robles, S. G., Zwinderman, A. H., Duffau, H. & Berger, M. S. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J. Clin. Oncol. 30, 2559–2565 (2012).
Brennum, J., Maier, C. M., Almdal, K., Engelmann, C. M. & Gjerris, M. Primo non nocere or maximum survival in grade 2 gliomas? A medical ethical question. Acta Neurochir. 157, 155–164 (2015).
Gulati, S., Jakola, A. S., Nerland, U. S., Weber, C. & Solheim, O. The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg. 76, 572–579 (2011).
Bette, S. et al. Patterns and time dependence of unspecific enhancement in postoperative magnetic resonance imaging after glioblastoma resection. World Neurosurg. 90, 440–447 (2016).
Grabowski, M. M. et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J. Neurosurg. 121, 1115–1123 (2014).
Molinaro, A. M. et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.6143 (2020).
Wijnenga, M. M. J. et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology 20, 103–112 (2018).
Press, R. H. et al. Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification. Cancer 126, 3255–3264 (2020).
Beiko, J. et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology 16, 81–91 (2014).
Walker, M. D. et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49, 333–343 (1978).
Keime-Guibert, F. et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356, 1527–1535 (2007).
Breen, W. G. et al. Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. Neuro-Oncology 22, 830–837 (2020).
Khan, L. et al. External beam radiation dose escalation for high grade glioma. Cochrane Database Syst. Rev. 5, CD011475 (2020).
Roa, W. et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. 22, 1583–1588 (2004).
Niyazi, M. et al. ESTRO-ACROP guideline ‘target delineation of glioblastomas’. Radiother. Oncol. 118, 35–42 (2016).
Harrabi, S. B. et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther. Onkol. 192, 759–769 (2016).
Malouff, T. D., Peterson, J. L., Mahajan, A. & Trifiletti, D. M. Carbon ion radiotherapy in the treatment of gliomas: a review. J. Neurooncol. 145, 191–199 (2019).
Nachbichler, S. B. & Kreth, F.-W. Brachytherapy of intracranial gliomas. Prog. Neurol. Surg. 31, 72–86 (2018).
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
Weller, M. & Le Rhun, E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat. Rev. 87, 102029 (2020).
Brem, H. et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008–1012 (1995).
Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5, 79–88 (2003).
Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology https://doi.org/10.1093/neuonc/noaa106 (2020).
Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580, 517–523 (2020).
Wick, W. et al. Lomustine and bevacizumab in progressive glioblastoma. N. Engl. J. Med. 377, 1954–1963 (2017).
Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733–4740 (2009).
Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745 (2009).
Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972 (2010).
van den Bent, M. J. et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 12, 583–593 (2011).
Radbruch, A. et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro-Oncology 17, 151–159 (2015).
Ellingson, B. M. et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology 17, 1188–1198 (2015).
Gui, C., Lau, J. C., Kosteniuk, S. E., Lee, D. H. & Megyesi, J. F. Radiology reporting of low-grade glioma growth underestimates tumor expansion. Acta Neurochir. 161, 569–576 (2019).
Zikou, A. et al. Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol. Imaging 2018, 6828396 (2018).
Pace, A. et al. European association for neuro-oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 18, e330–e340 (2017).
Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344–1355 (2016).
Wahl, M. et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro-Oncology 19, 242–251 (2017).
Rudà, R. et al. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. J. Neurooncol. 145, 115–123 (2019).
Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874–5880 (2009).
Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337–343 (2013).
van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344–350 (2013).
Habets, E. J. J. et al. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J. Neurooncol. 116, 161–168 (2014).
Wick, W. et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology 18, 1529–1537 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00887146 (2020).
Jakola, A. S. et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann. Oncol. 28, 1942–1948 (2017).
van den Bent, M. J. et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366, 985–990 (2005).
Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1521–1532 (2016).
Bell, E. H. et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: A phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J. Clin. Oncol. 38, 3407–3417 (2020).
van den Bent, M. J. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet https://doi.org/10.1016/S0140-6736(17)31442-3 (2017).
van den Bent, M. et al. ACTR-11. Second interim and 1st molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. Neuro-Oncology 21, vi14–vi14 (2019).
Yung, W. K. et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2762–2771 (1999).
Brada, M. et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol. 28, 4601–4608 (2010).
Vuorinen, V., Hinkka, S., Färkkilä, M. & Jääskeläinen, J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir. 145, 5–10 (2003).
Roa, W. et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 33, 4145–4150 (2015).
Perry, J. R. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N. Engl. J. Med. 376, 1027–1037 (2017).
Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707–715 (2012).
Wick, A. et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. Neuro-Oncology https://doi.org/10.1093/neuonc/noaa033 (2020).
Malmström, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916–926 (2012).
Weller, M. Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? Cancer 124, 1316–1318 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02617589 (2020).
Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306–2316 (2017).
Taphoorn, M. J. B. et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4, 495–504 (2018).
Bernard-Arnoux, F. et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro-Oncology 18, 1129–1136 (2016).
Gilbert, M. R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J. Clin. Oncol. 31, 4085–4091 (2013).
Balana, C. et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01). Neuro-Oncology https://doi.org/10.1093/neuonc/noaa107 (2020).
Herrlinger, U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393, 678–688 (2019).
Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014).
Gilbert, M. R., Sulman, E. P. & Mehta, M. P. Bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 2048–2049 (2014).
Wirsching, H.-G. et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann. Oncol. 29, 1423–1430 (2018).
Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).
Suchorska, B. et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology 18, 549–556 (2016).
Ryu, S. et al. The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 118, 489–499 (2014).
Tsien, C. et al. ACTR-32. NRG ONCOLOGY RTOG 1205: randomized phase II trial of concurrent bevacizumab and re-irradiation vs. bevacizumab alone as treatment for recurrent glioblastoma. Neuro-Oncology 21, vi20–vi20 (2019).
Batchelor, T. T. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28, 2817–2823 (2010).
Becker Buxton, M. et al. GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. J. Clin. Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS2579 (2020).
Perry, J. R. et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28, 2051–2057 (2010).
Weller, M. et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin. Cancer Res. 21, 2057–2064 (2015).
Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.1024 (2020).
Stupp, R. et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192–2202 (2012).
Kaley, T. et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J. Clin. Oncol. 36, 3477–3484 (2018).
Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425–437 (2012).
Pitter, K. L. et al. Corticosteroids compromise survival in glioblastoma. Brain 139, 1458–1471 (2016).
Hovey, E. J. et al. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. Neurooncol Pract. 4, 171–181 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03763422 (2020).